logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • Medications for Chronic Lymphocytic Leukemia

    FiltersReset Filters
    14 results

    • bendamustine hydrochloride

      (bendamustine hydrochloride)
      Baxter Healthcare Corporation
      Usage: Bendamustine Hydrochloride Injection is indicated for adult patients with chronic lymphocytic leukemia (CLL) and for those with indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.

    • brukinsa

      (zanubrutinib)
      BEIGENE USA, INC.
      Usage: BRUKINSA is indicated for treating adult patients with mantle cell lymphoma, Waldenström's macroglobulinemia, relapsed or refractory marginal zone lymphoma, chronic lymphocytic leukemia or small lymphocytic lymphoma, and relapsed or refractory follicular lymphoma in combination with obinutuzumab, after prior therapies.

    • calquence

      (acalabrutinib)
      AstraZeneca Pharmaceuticals LP
      Usage: CALQUENCE is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who are ineligible for autologous stem cell transplantation, previously treated MCL patients, and those with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

    • copiktra

      (duvelisib)
      Secura Bio, Inc.
      Usage: COPIKTRA is indicated for treating adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL) who have undergone at least two prior therapies.

    • cyclophosphamide

      (Cyclophosphamide)
      NorthStar RxLLC
      Usage: Cyclophosphamide for injection is indicated for treating various malignant diseases, including advanced lymphomas, multiple myeloma, leukemias, mycosis fungoides, neuroblastoma, ovarian adenocarcinoma, retinoblastoma, and breast carcinoma. It is also used for pediatric patients with minimal change nephrotic syndrome who do not respond to corticosteroids.

    • cyclophosphamide

      (cyclophosphamide)
      Baxter Healthcare Corporation
      Usage: Cyclophosphamide for Injection is indicated for treating various malignancies in adults and pediatric patients, including malignant lymphomas, multiple myeloma, leukemias, and specific cancers like breast and ovarian carcinoma. It's also used for pediatric minimal change nephrotic syndrome when corticosteroid therapy fails.

    • cyclophosphamide

      (Cyclophosphamide)
      Amneal Pharmaceuticals LLC
      Usage: Cyclophosphamide for injection is indicated for treating various malignant diseases, including specific types of lymphomas, multiple myeloma, leukemias, mycosis fungoides, neuroblastoma, and certain carcinomas. It is also used in pediatric patients with biopsy-proven minimal change nephrotic syndrome who do not respond to steroid therapy.

    • cyclophosphamide

      (cyclophosphamide)
      Bamboo US Bidco LCC
      Usage: Cyclophosphamide is indicated for treating various malignant diseases, including lymphomas, multiple myeloma, leukemias, mycosis fungoides, neuroblastoma, ovarian adenocarcinoma, retinoblastoma, and breast carcinoma. It is also used for pediatric minimal change nephrotic syndrome unresponsive to corticosteroids. Safety in adults for this condition is not established.

    • gazyva

      (obinutuzumab)
      Genentech, Inc.
      Usage: GAZYVA is indicated for treating chronic lymphocytic leukemia (CLL) in combination with chlorambucil, and for follicular lymphoma (FL) in combination with bendamustine or chemotherapy, followed by monotherapy. It is used for relapsed/refractory FL post-rituximab and for untreated stage II bulky, III or IV FL.

    • imbruvica

      (Ibrutinib)
      Pharmacyclics LLC
      Usage: IMBRUVICA is indicated for adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), CLL/SLL with 17p deletion, Waldenström’s macroglobulinemia, and for treating chronic graft-versus-host disease in patients aged 1 year and older after failure of prior systemic therapy.